Xinnatehttps://validator.w3.org/feed/docs/rss2.htmlModes of actionApproved clinical trial application for First in Human study on BioC gelXinnate AB partners with Destum Partners, Inc. a leading global, advisory firmXinnate receives Orphan Drug Designation from US FDA for TCP-25TeamOpportunityScientific FoundationPublicationsAboutApproved clinical trial application for BioC gel on complex woundsXinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis BullosaXinnate presents TCP-25 data at international dermatology congressPhase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis BullosaXinnate completes Phase 1a/b study with TCP-25ContactNewsUpcoming eventsThe Unique ConceptThe NeedThe MarketHome 2Xinnate announces successful FDA meeting for TCP-25Test news itemExcellent results from phase I study shows that the BioC gel is safe and well tolerated.Funding secured for the next step of BioC clinical planThe CompetitionIdeaConceptXinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis BullosaXinnate appoints Anna-Karin Lindqvist as new COOTest News 2Pre-clinical resultsTest News 3Xinnate is awarded a prestigious grant from the US Department of DefenseStrategyNew publication: BioC-coated dressing shows promising effect on both infection and inflammationFunding secured for the first clinical study of BioC wound gelXinnate has received a prestigious Swedish Research Council grantGreat interest for the STM article and coverage in Nature Reviews Drug DiscoveryKnowledge PlatformBreakthrough results published in Science Translational MedicineXinnate is looking for a Chief Operating OfficerIntegritetspolicyA new article about BioC results from Lund UniversityIPRExempelsidaHome4